Lung Cancer Clinical Trials Overview

SCCA Clinical Studies: Lung Cancer

MEDI4736 (Anti PD-L1) w/ Gefitinib for Non-Small Cell Lung Cancer (UW14005)
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Gefitinib in Combination With MEDI4736 (Anti PD-L1) in Subjects With Non-Small Cell Lung Cancer(NSCLC)
Status Conditions Phase Study ID
Closed Non-Small Cell Lung Cancer Phase I UW14005

This a Phase I, Open-Label, Multicentre Study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of gefitinib in combination with MEDI4736 (anti PD-L1) in Subjects with Non-small cell lung cancer (NSCLC). The study consists of two phases: Escalation phase and an expansion phase to be conducted in locally advanced or metastatic NSCLC subjects

Laura Chow, MD
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  1. Provision of signed and dated, written informed consent
  2. Male or female aged 18 years and older.
  3. Subjects must have in the Expansion Phase, locally advanced or metastatic NSCLC subjects who have an EGFR mutation and have not received any systemic therapy.
  4.  For the Expansion Phase: At least one measurable lesion.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusions (conditions that would prevent participation in this study)
  1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment.
  2. Any investigational agent, chemotherapy, immunotherapy, biologic, hormonal within 28 days of the first dose of study treatment
  3. Inadequate bone marrow reserve or organ function
Last Updated
January 26, 2015
See this trial at
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.